Blume Ventures

Blume Ventures is one of the most active and respected early-stage investors in India, writing pre-seed, seed, and early Series A checks across a portfolio that spans hundreds of companies. Check sizes typically range from $250K to $1M at the entry point, with substantial follow-on capacity through later funds, and the firm has been deploying from Fund V at a pace consistent with its long-running commitment to Indian early-stage technology. Within healthcare, Blume has been a credible backer of AI-driven healthcare platforms, including Confido Health, the Series A-stage AI voice agent platform now scaling in the US healthcare market that Blume led in 2025 alongside Schema Ventures and Vicus Ventures. That deal illustrates Blume’s willingness to back Indian-rooted teams attacking US healthcare with applied AI, and it is a useful signal of how the firm thinks about the intersection of Indian engineering and global commercial markets. The geographic focus is India with a globally ambitious portfolio, and the Blume partner team is deeply networked into the broader Indian operator and engineering community. The right founder profile is an early-stage Indian-rooted technical founder building applied AI, digital health workflow software, or health IT platforms with a credible global commercial thesis, particularly one that targets US enterprise healthcare buyers from an Indian engineering base. The wrong fit is a pure consumer wellness brand without technology defensibility, or a deep-science biotech requiring specialist diligence and patient capital. The right entry path is through Bengaluru and Mumbai founder networks, through alumni of companies like Razorpay, Freshworks, and Postman, and through warm introductions from co-investors and from Blume’s broader portfolio CEO network. The firm is reachable through targeted outreach when the product is sharp, but warm referrals materially compress diligence. When pitching, lead with the founder-market fit, the technical defensibility, and the path to durable enterprise revenue, then layer in the AI capability that genuinely changes the cost or outcome curve in healthcare. Caveats: Blume is a generalist early-stage investor rather than a healthcare specialist, so founders should expect strong general operator support but should bring in clinical-domain advisors and specialist co-investors as the company scales. Use Blume as the credible Indian early partner for a globally ambitious AI-for-healthcare company.